Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Series A funding round led by Angelini Ventures’, the investment arm of Italian industrial group Angelini Industries. The ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

Gilead Sciences' Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Squibb over patents relating to CAR-T therapies, overturning a $1.2 billion fine levied ...

In the biotechnology and chemical spaces, genus claims are often sought by patent applicants to protect not only a specific product of interest, ...

As principal and co-founder of Sierra Pacific Constructors and a second-generation builder, Cary Gerhardt remains active in ...

Sierra Pacific Constructors principal and cofounder Ken La Spada is responsible for a wide diversity of activities for SPC, ...

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...

Whatever you do, don’t call it a festival. There’s no set schedule or events during the two-day gathering, warns Dave Shenkman, owner of Kite Connection on the Huntington Beach Pier and ...